• CDRH: Center for Devices and Radiological Health
• CBER: Center for Biologics Evaluation and Research
• CDER: Center for Drug Evaluation and Research
In some cases, a therapeutic or diagnostic product might combine drugs, devices, and/or biological products. The FDA classifies these products as combination products. This may be,
(i) A product comprised of two or more regulated components, i.e., drug/device, biologic/device, drug/biologic, or drug/device/biologic, that are physically, chemically, or otherwise combined or mixed and produced as a single entity; or
(ii) Two or more separate products packaged together in a single package or as a unit.
Example: Drug eluting stent - It combines device and drug.
In such scenarios, it is essential to determine which FDA center gets jurisdiction of the product. It is usually determined by two main questions:
– What is the primary mode of action of the product?
– Is it a drug, biologic, or device?
If there still is any confusion, the FDA allows the manufacturer to submit a Request For Designation (RFD) form, so that the FDA can decide the primary jurisdiction for the combination product. This is to be done before filing any other device-related document to the FDA. The FDA considers the
• Primary Mode of Action
• Previous Determinations for Precedent and
• Sponsor's request with a justification
before it makes a determination.
Example: In the case of a drug eluting stent, it was classified primarily as a device, since its primary mode of action is to prevent localized vessel/flow constriction. The drug is eluted as a secondary action to prevent fibrosis and eventually re-stenosis. Hence, the product was primarily assigned to CDRH and was to consult CDER as well.
No comments:
Post a Comment